Share
1,206 Posts.
lightbulb Created with Sketch. 116
clock Created with Sketch. 12/10/18
21:57
Share
Originally posted by hottod
↑
Is anyone interested in which individual in the company planted the seed to go down the path of suing Mylan for inherited apparent patent infringements involving the daptomycin injectable product? The TPM®/Daptomycin licencing agreement signed in 2012 forms part of the arbitration dispute with Mylan. To date Mylan has not launched the TPM®/Daptomycin product and Phosphagenics has not been informed by Mylan of either its registration or launch plans. Therefore Phosphagenics is not aware of when it might begin to receive royalty payments it is entitled to under the licencing agreement. (2016 Annual Report)In January 2016, Phosphagenics lodged a dispute notice in association with the Agila TPM®/Daptomycin agreements. In accordance with the relevant agreements, the dispute was referred to arbitration in Singapore.
Expand
Memory of an elephant. Much appreciated.
(20min delay)